It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tertiary lymphoid structures (TLS) are lymph node-like immune cell clusters that emerge during chronic inflammation in non-lymphoid organs like the kidney, but their origin remains not well understood. Here we show, using conditional deletion strategies of the canonical Notch signaling mediator Rbpj, that loss of endothelial Notch signaling in adult mice induces the spontaneous formation of bona fide TLS in the kidney, liver and lung, based on molecular, cellular and structural criteria. These TLS form in a stereotypical manner around parenchymal arteries, while secondary lymphoid structures remained largely unchanged. This effect is mediated by endothelium of blood vessels, but not lymphatics, since a lymphatic endothelial-specific targeting strategy did not result in TLS formation, and involves loss of arterial specification and concomitant acquisition of a high endothelial cell phenotype, as shown by transcriptional analysis of kidney endothelial cells. This indicates a so far unrecognized role for vascular endothelial cells and Notch signaling in TLS initiation.
Loss of canonical Notch signaling in vascular endothelial cells induces spontaneous formation of proto-typical tertiary lymphoid structures in mouse kidney, liver and lungs, which form around central arteries that acquire a high endothelial cell signature
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details













1 Hannover Medical School, Vascular Medicine Research, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877); Hannover Medical School, Department of Nephrology and Hypertension, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877); RWTH Aachen University Hospital, Department of Geriatric Medicine (Medical Clinic VI), Aachen, Germany (GRID:grid.412301.5) (ISNI:0000 0000 8653 1507)
2 Hannover Medical School, Vascular Medicine Research, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877); Hannover Medical School, Department of Nephrology and Hypertension, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
3 Department of Oncology UNIL CHUV and Ludwig Institute for Cancer Research, Vascular and Tumor Biology Laboratory, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204)
4 University Hospital Essen, Department of Immunodynamics, Institute for Experimental Immunology and Imaging, Medical Research Centre, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331)
5 Department of Oncology UNIL CHUV and Ludwig Institute for Cancer Research, Vascular and Tumor Biology Laboratory, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204); SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland (GRID:grid.419765.8) (ISNI:0000 0001 2223 3006)
6 Member of the German Center for Lung Research (DZL), Hannover Medical School, Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), Hannover, Germany (GRID:grid.452624.3)
7 Hannover Medical School, Department of Nephrology and Hypertension, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
8 Max-Planck-Institute for Molecular Biomedicine, Muenster, Germany (GRID:grid.461801.a) (ISNI:0000 0004 0491 9305)
9 Member of the German Center for Lung Research (DZL), Hannover Medical School, Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), Hannover, Germany (GRID:grid.452624.3); Hannover Medical School, Department of Pediatric Pneumology, Allergology and Neonatology, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
10 Hannover Medical School, Institute of Immunology, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
11 Hannover Medical School, Department of Cardiology and Angiology, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
12 Hannover Medical School, Department of Nephrology and Hypertension, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877); UKB Bonn University Hospital, Division of Medicine I, Nephrology section, Bonn, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X)
13 Hannover Medical School, Department of Cardiology and Angiology, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877); Medical Faculty of the Philipps University Marburg, Department of Cardiovascular Complications of Oncologic Therapies, Marburg, Germany (GRID:grid.10253.35) (ISNI:0000 0004 1936 9756)